Brief: Cadrenal Therapeutics Engages The Sage Group To Advance Tecarfarin's Late-Stage Development And Commercialization
12/12/2023 14:03
Dec 12 (Reuters) - Cadrenal Therapeutics Inc CVKD.O :
* CADRENAL THERAPEUTICS ENGAGES THE SAGE GROUP TO ADVANCE
TECARFARIN'S LATE-STAGE DEVELOPMENT AND COMMERCIALIZATION
Source text for Eikon: ID:nPndMK9xa
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology